Hongkou Capital

Day Zero Diagnostics Inc. is an innovative company focused on transforming infectious disease diagnostics through advanced sequencing technologies. Based in Boston, Massachusetts, the company has developed a rapid diagnostic system that identifies bacterial species and their antibiotic resistance profiles directly from clinical samples. Key technologies include Blood2Bac, which enriches bacterial DNA, and BacDetect, allowing for swift detection of bacterial DNA. Additionally, the company employs machine learning algorithms for genomic antibiotic susceptibility testing and maintains a comprehensive microbial database that integrates genomic sequencing data with resistance profiles. By enabling rapid and accurate diagnoses, Day Zero Diagnostics aims to address critical needs in managing bloodstream infections and sepsis, reducing the time for diagnosis from days to hours and improving patient outcomes through targeted treatments.

Amionx is a leader in the development of safe battery technology aimed at preventing lithium-ion batteries from causing fires or explosions. The company's innovative Safe Core technology functions like a circuit breaker, providing enhanced safety without compromising battery performance. This technology is applicable across various battery chemistries, including solid-state batteries, allowing original equipment manufacturers (OEMs) to mitigate the risks associated with overcharging, internal shorts, and external heat. By prioritizing safety from the core outward, Amionx addresses critical concerns in the battery industry, enabling safer usage of batteries in a range of applications.